AU2008200576A1 - Lipolytic enzyme variants and method for their production - Google Patents
Lipolytic enzyme variants and method for their production Download PDFInfo
- Publication number
- AU2008200576A1 AU2008200576A1 AU2008200576A AU2008200576A AU2008200576A1 AU 2008200576 A1 AU2008200576 A1 AU 2008200576A1 AU 2008200576 A AU2008200576 A AU 2008200576A AU 2008200576 A AU2008200576 A AU 2008200576A AU 2008200576 A1 AU2008200576 A1 AU 2008200576A1
- Authority
- AU
- Australia
- Prior art keywords
- amino acid
- lipolytic enzyme
- activity
- variant
- phospholipase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004190 Enzymes Human genes 0.000 title claims description 96
- 108090000790 Enzymes Proteins 0.000 title claims description 96
- 230000002366 lipolytic effect Effects 0.000 title claims description 78
- 238000000034 method Methods 0.000 title claims description 35
- 238000004519 manufacturing process Methods 0.000 title description 5
- 230000000694 effects Effects 0.000 claims description 66
- 239000000758 substrate Substances 0.000 claims description 44
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 42
- 102000015439 Phospholipases Human genes 0.000 claims description 42
- 108010064785 Phospholipases Proteins 0.000 claims description 42
- 102220271537 rs200383861 Human genes 0.000 claims description 40
- 102200108133 rs201753350 Human genes 0.000 claims description 38
- 108090001060 Lipase Proteins 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 102000004882 Lipase Human genes 0.000 claims description 28
- 230000004075 alteration Effects 0.000 claims description 28
- 239000004367 Lipase Substances 0.000 claims description 24
- 235000019421 lipase Nutrition 0.000 claims description 24
- 102100031415 Hepatic triacylglycerol lipase Human genes 0.000 claims description 19
- 108020002496 Lysophospholipase Proteins 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 241000223258 Thermomyces lanuginosus Species 0.000 claims description 15
- 230000003301 hydrolyzing effect Effects 0.000 claims description 15
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 102200059764 rs28942097 Human genes 0.000 claims description 12
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 241000223221 Fusarium oxysporum Species 0.000 claims description 7
- 238000012360 testing method Methods 0.000 claims description 7
- FROLUYNBHPUZQU-IIZJPUEISA-N (2R,3R,4S,5R)-2-(hydroxymethyl)-6-[3-[3-[(3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropoxy]propoxy]oxane-3,4,5-triol Chemical compound OC[C@H]1OC(OCCCOCCCOC2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@H]1O FROLUYNBHPUZQU-IIZJPUEISA-N 0.000 claims description 6
- 230000002538 fungal effect Effects 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000001924 fatty-acyl group Chemical group 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102220492352 DDRGK domain-containing protein 1_E87A_mutation Human genes 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 claims description 3
- 241000223218 Fusarium Species 0.000 claims description 3
- 102220358508 c.297A>T Human genes 0.000 claims description 3
- 235000019626 lipase activity Nutrition 0.000 claims description 3
- 102200135781 rs1042140 Human genes 0.000 claims description 3
- 102220087418 rs864622444 Human genes 0.000 claims description 3
- 241000223257 Thermomyces Species 0.000 claims description 2
- 101000984201 Thermomyces lanuginosus Lipase Proteins 0.000 claims description 2
- 125000000524 functional group Chemical group 0.000 claims description 2
- 102220100163 rs201567345 Human genes 0.000 claims description 2
- 102220011160 rs730880501 Human genes 0.000 claims description 2
- 230000000875 corresponding effect Effects 0.000 claims 6
- 102220489655 Serine/threonine-protein kinase D1_R84A_mutation Human genes 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 description 80
- 229940024606 amino acid Drugs 0.000 description 20
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 15
- 235000013312 flour Nutrition 0.000 description 12
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 10
- 239000000787 lecithin Substances 0.000 description 10
- 229940067606 lecithin Drugs 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 8
- 239000004382 Amylase Substances 0.000 description 6
- 108010065511 Amylases Proteins 0.000 description 6
- 102000013142 Amylases Human genes 0.000 description 6
- 235000019418 amylase Nutrition 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- -1 glycerol Chemical class 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 3
- 240000006439 Aspergillus oryzae Species 0.000 description 3
- 244000075850 Avena orientalis Species 0.000 description 3
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 102100033357 Pancreatic lipase-related protein 2 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 108090000344 1,4-alpha-Glucan Branching Enzyme Proteins 0.000 description 2
- 102000003925 1,4-alpha-Glucan Branching Enzyme Human genes 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 2
- 235000007558 Avena sp Nutrition 0.000 description 2
- 239000004156 Azodicarbonamide Substances 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 102220618642 Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe_R84A_mutation Human genes 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- 102100034866 Kallikrein-6 Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 description 2
- 108020002334 Monoacylglycerol lipase Proteins 0.000 description 2
- QUZHZFAQJATMCA-UHFFFAOYSA-N Monogalactosyldiglyceride Natural products CCC=CCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCC=CCC)COC1OC(CO)C(O)C(O)C1O QUZHZFAQJATMCA-UHFFFAOYSA-N 0.000 description 2
- 102100029814 Monoglyceride lipase Human genes 0.000 description 2
- 229910017974 NH40H Inorganic materials 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- XOZUGNYVDXMRKW-AATRIKPKSA-N azodicarbonamide Chemical compound NC(=O)\N=N\C(N)=O XOZUGNYVDXMRKW-AATRIKPKSA-N 0.000 description 2
- 235000019399 azodicarbonamide Nutrition 0.000 description 2
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108020003519 protein disulfide isomerase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940100486 rice starch Drugs 0.000 description 2
- 102220274708 rs1555866028 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical class CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- DRCWOKJLSQUJPZ-DZGCQCFKSA-N (4ar,9as)-n-ethyl-1,4,9,9a-tetrahydrofluoren-4a-amine Chemical compound C1C2=CC=CC=C2[C@]2(NCC)[C@H]1CC=CC2 DRCWOKJLSQUJPZ-DZGCQCFKSA-N 0.000 description 1
- XWNSFEAWWGGSKJ-UHFFFAOYSA-N 4-acetyl-4-methylheptanedinitrile Chemical compound N#CCCC(C)(C(=O)C)CCC#N XWNSFEAWWGGSKJ-UHFFFAOYSA-N 0.000 description 1
- 108010043797 4-alpha-glucanotransferase Proteins 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- 241001375492 Absidia reflexa Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000892910 Aspergillus foetidus Species 0.000 description 1
- 241000228232 Aspergillus tubingensis Species 0.000 description 1
- 241000193744 Bacillus amyloliquefaciens Species 0.000 description 1
- 241000194108 Bacillus licheniformis Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101001007681 Candida albicans (strain WO-1) Kexin Proteins 0.000 description 1
- 101710128063 Carbohydrate oxidase Proteins 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 102100023441 Centromere protein J Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 241000146406 Fusarium heterosporum Species 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000907924 Homo sapiens Centromere protein J Proteins 0.000 description 1
- 101001008429 Homo sapiens Nucleobindin-2 Proteins 0.000 description 1
- 101000693082 Homo sapiens Serine/threonine-protein kinase 11-interacting protein Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 108010008292 L-Amino Acid Oxidase Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 102000007070 L-amino-acid oxidase Human genes 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 101710117655 Maltogenic alpha-amylase Proteins 0.000 description 1
- 102100027441 Nucleobindin-2 Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100035200 Phospholipase A and acyltransferase 4 Human genes 0.000 description 1
- 102100037883 Phospholipase B1, membrane-associated Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 239000004153 Potassium bromate Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000303962 Rhizopus delemar Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100022833 Serum paraoxonase/lactonase 3 Human genes 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101000733590 Streptomyces griseus subsp. griseus (strain JCM 4626 / NBRC 13350) Aminopeptidase S Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108060008539 Transglutaminase Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 108010009043 arylesterase Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 108010019077 beta-Amylase Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012777 crisp bread Nutrition 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- YERABYSOHUZTPQ-UHFFFAOYSA-P endo-1,4-beta-Xylanase Chemical compound C=1C=CC=CC=1C[N+](CC)(CC)CCCNC(C(C=1)=O)=CC(=O)C=1NCCC[N+](CC)(CC)CC1=CC=CC=C1 YERABYSOHUZTPQ-UHFFFAOYSA-P 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 229940031098 ethanolamine Drugs 0.000 description 1
- 108010041969 feruloyl esterase Proteins 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000003903 lactic acid esters Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- YAFQFNOUYXZVPZ-UHFFFAOYSA-N liproxstatin-1 Chemical compound ClC1=CC=CC(CNC=2C3(CCNCC3)NC3=CC=CC=C3N=2)=C1 YAFQFNOUYXZVPZ-UHFFFAOYSA-N 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 235000012796 pita bread Nutrition 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000223 polyglycerol Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000019396 potassium bromate Nutrition 0.000 description 1
- 229940094037 potassium bromate Drugs 0.000 description 1
- JLKDVMWYMMLWTI-UHFFFAOYSA-M potassium iodate Chemical compound [K+].[O-]I(=O)=O JLKDVMWYMMLWTI-UHFFFAOYSA-M 0.000 description 1
- 239000001230 potassium iodate Substances 0.000 description 1
- 235000006666 potassium iodate Nutrition 0.000 description 1
- 229940093930 potassium iodate Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108010001816 pyranose oxidase Proteins 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 102220094506 rs876659390 Human genes 0.000 description 1
- 102220279444 rs988441570 Human genes 0.000 description 1
- 235000012780 rye bread Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 235000012184 tortilla Nutrition 0.000 description 1
- 102000003601 transglutaminase Human genes 0.000 description 1
- 235000012794 white bread Nutrition 0.000 description 1
- 235000012799 wholemeal bread Nutrition 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
S&F Ref: 675753D1
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
\O
O In oo o i Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Novozymes A/S, of Krogshojvej 36, DK-2880, Bagsvaerd, Denmark Luise Christiansen, Hans Peter Heldt-Hansen, Allan Svendsen, Jesper Vind Spruson Ferguson St Martins Tower Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Lipolytic enzyme variants and method for their production The following statement is a full description of this invention, including the best method of performing it known to me/us: 5845c(1120533_1) 00 LIPOLYTIC ENZYME VARIANTS AND METHOD FOR THEIR PRODUCTION FIELD OF THE INVENTION The present invention relates to a lipolytic enzyme variant and a method of producing such a variant. More particularly, the variant has a relatively high activity for one ester bond in an amphiphilic substrate with two lipophilic groups and a relatively low activity for the ester bond in an amphiphilic substrate with one lipophilic group, e.g. a relatively high phospholipase activity and a relatively low lysophospholipase activity.
SBACKGROUND OF THE INVENTION 0 EP 870840, JP-A 10-42884, JP-A 4-135456 or JP-A 2-49593 describe the use of a phospholipase to hydrolyze a phospholipid to produce lysophospholipid.
JUS 4567046, WO 94/04035, EP 109244, EP 585988, WO 98/26057, IWO 98/45453, WO 99/53769, WO 00/32758, IhO 0139602 and EP 575133 describe the addition of various lipolytic enzymes to dough in the preparation of baked products and the preparation of lipolytic enzyme variants.
IWO 00/32758) discloses that the substrate specificity of a lipolytic enzyme can be modified by making alterations to the amino acid sequence.
SUMMARY OF THE INVENTION The inventors have developed a method using protein engineering to produce lipolytic enzymes having a relatively high activity for one ester bond in an amphiphillc substrate with two lipophilic groups and a relatively low activity for the ester bond in an amphiphilic substrate with one lipophilic group, e.g. a relatively high phospholipase activity and a relatively low lysophospholipase activity.
Accordingly, the invention provides a method of producing a lipolytic enzyme variant comprising: a) selecting a parent fungal lipolytic enzyme, b) in the parent lipolytic enzyme altering at least one specified amino acid residue, c) optionally, altering one or more amino acid residues other than b), d) preparing the variant resulting from steps e) testing hydrolytic activities of the variant towards a first substrate and a second substrate, f) selecting a variant having a ratio of hydrolytic activities towards the first substrate and the second substrate which is lower than the parent lipolytic enzyme, and g) producing the selected variant.
O The first substrate is a molecule comprising one fatty acyl group linked through an N ester or thioester bond to a hydrophilic group. The second substrate is a molecule comprising Sa first lipophilic group which Is a fatty acyl group linked through an ester or thioester bond to a S hydrophilic group, and a second lipophilic group linked to the hydrophilic group, where the second lipolhilic group may be a second fatty acyl group linked through an ester, thioester or amide bond, or it may be a fatty alcohol linked through an ether or thioether bond.
IN Each amino acid alteration may be an amino acid substitution, deletion or insertion.
SThe amino acid residue to be altered may be determined from a three-dimensional model of a phospholipid docked with the parent lipolytic enzyme as a residue which comprises an atom cN (excluding H atoms) which lies within 10 A (particularly 7 A or 5 A) of an atom (excluding H 00 Satoms) of the lyso-phospholipid, or it may be the C-terminal amino acid.
SAlternatively, the amino acid residue to be altered may be determined by aligning the amino acid sequence of the parent lipolytic enzyme with the T. lanuginosus lipase and selecting a residue corresponding to any of residues 17-18, 20-23, 26, 37, 39, 62, 64, 80-96, 110- 113, 144-151, 171-177, 200-211, 213, 215, 227, 253-261 or 263-269.
The invention also provides a 1. lipolytic enzyme having an amino acid sequence derived from the T. lanuginosus lipase (SEQ ID NO: 14) comprising the following amino acid alterations: a) R84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N, b) G91A +D96W +E99K +L227G +G263Q +L264A +1265T +G266D +T267A +L269N, c) R84W +G91A:D96F +E99K +G263Q +L264A +1265T +G266S +T267A +L269N +270A +271G +272G +273F +274S, d) SPPCGRRP(-E) +Y21K +E99N +N101S +E239C +Q249R, e) G91A +D96K +E99K +G263Q +L264A +1265T +G266D +T267A +L269N, f) Y21V +R84G +G91A:D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, g) V60G +D62W +R84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N, h) V60A +D62S +G91A +D96W +E99K +W221R +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, i) R84A S85D E87A +G91A +D96G +K98E +E99D, j) G91A +D96W +E99K +P250N +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, 00 k) (391A +D96W +E99K +P256N +G263Q +L264A +1265T +G266D +T267A +1_269N +270A +271 G +272G +273F +274S, CI1) R84W +G9IA +D96W +E99K +Y261Q +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S, M) G91A +D96W +E99K +P250L +P253Q +D254DEL ff2575 +G263Q r- +1-264A +1265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S, n) R84Y G91A D96F E99K G263Q L264A 1265T G266D T267A L269N, or In R84S G91A D96F E99K E129A +V203i +1-206F G263Q L264A 1265T G266D T267A L269N.
The invention also provides a lipolytic enzyme having an amino acid sequence derived from a Fusariumn lipase comprising at least one amino acid alteration corresponding to C1 the following In the Fusarium oxysporumn lipase(phospholipase (SEQ ID NO: 7): a) H257W, b) S142A, c) V1571), d) S271P, e) S8OT, I) Al 27T, g) D263G, h) Y2I1W, i) D) R274A, k) 275YRSAESVDKR or 1) 275YRSAESVDKAATMTDAELEKKLNSWVQMDKEYVKNNQARS.
Further, the Invention provides a lipolytic enzyme which: a) has an amino acid sequence having at least 90 Identity to that of the Thermomyces Ianuginosus lipase or the Fusarium oxysporum lipase/phospholipase, b) has phospholipase activity, and c) has a lysophospholipase to phospholipase ratio below the limit Indicated below.
DETAILED DESCRIPTION OF THE INVENTION Test substrates The invention uses two different polar lipids as test substrates. Both are amphiphilic (amphipolaric), having a hydrophilic part and one or two lipophilic groups, respectively.
First substrate 00 The first substrate has the general formula A-B-C where: S* A is an acyl group, particularly straight-chain and unsubstituted. It may be satu- Srated or may have one or more double bonds. It may have an even number of car- [T 5 bon atoms, e.g. from 12 to 24 B is O (oxygen) or S (sulfur) forming an ester or thioester bond between A and C.
C is a polyol having B attached to an OH group, optionally having other functional 0 groups and/or a hydrophilic group attached to an OH group. The polyol may be a sugar alcohol such as glycerol, e.g. having B attached in the snl or sn2 position of glycerol. The other functional groups may be one or more aldehyde, keto or carboxyl C groups; thus, the polyol may be a monosaccharide or a corresponding uronic acid.
SThe hydrophilic group linked to an OH group, e.g. in the sn3 position of glycerol, may be: o A phosphate group, optionally linked to an alcohol such as choline, ethanolamine, serine or inositol.
o Mono- or digalactosyl link to C through a glycosidic bond.
The first substrate may be a lysophospholipid such as lyso-lecithin or a lysogalactolipid such as digalactosyl monoglyceride (DGMG) or monogalactosyl monoglyceride (MGMG). The lyso-phospholipid may be a 1-lyso-phospholipid with an acyl group at the snlposition or a 2-lyso-phospholipid with an acyl group at the sn2-position.
The activity of interest is a hydrolytic activity towards the bond B-C.
Second substrate The second substrate has the general formula C where: A' is an acyl group defined as for A above.
B' is O (oxygen) or S (sulfur) forming an ester or thioester bond between A' and C.
A" is an acyl or alkyl group particularly straight-chain and unsubstituted. It may be saturated or may have one or more double bonds. It may have an even number of carbon atoms, e.g. from 12 to 24 B" is O (oxygen), S (sulfur) or NH forming an ester, thioester, amide, ether or thioether bond between A" and C.
C is the same as for the first substrate.
A" and B" of the second substrate may be chosen identical to A and B of the second substrate and attached in the same position of C, or they may be chosen independently.
The second substrate may be a phospholipid such as lecithin or a galactollpid such as digalactosyl diglyceride (DGDG) or monogalactosyl diglyceride (MGDG), or it may be pre- 00 pared synthetically by attaching a fatty alcohol through an ether bond or thioether bond to a lysophospholipid or a lyso-galactolipid.
SThe activity of interest Is a hydrolytic activity towards the B'-C bond.
SLipolytic enzyme activities The lipolytic enzyme of the invention has a low ratio of activity for the first substrate compared to activity for the second substrate. Thus, it has a relatively low hydrolytic activity O towards the B-C (thio)ester bond of the first substrate and a relatively high hydrolytic activity towards the B'-C (thio)ester bond of the second substrate. The activity towards the second substrate may be phospholipase Al (EC 3.1.1.32) or A2 (EC or it may be a galactolipase activity.
O The activity ratio may be found by contacting the lipolytic enzyme with each sub- S strate separately or by contacting it with a mixture including both substrates. The activity ratio may be measured by the PLARN assay, the RLPLA assay or a plate assay described below.
The lipolytic enzyme may have a ratio of lysophospholipase activity to phospholipase activity corresponding to PLARN below 1000 (particularly 500, below 200 or below 50) or RLPLA below 2 (particularly below 1 or below The lipolytic enzyme of the invention may have phospholipase (PL) activity with a relatively low lysophospholipase (LPL) activity. The lyso-phospholipid may be a 1-lysophospholipid with an acyl group at the snl-position or a 2-lyso-phospholipid with an acyl group at the sn2-position. The lipolytic enzyme may in particular have phospholipase Al activity with low 1-lysophospholipase activity.
The lipolytic enzyme of the invention may have hydrolytic activity towards a carboxylic ester bond In DGDG (digalactosyl diglyceride) with a relatively low hydrolytic activity towards the ester bond in DGMG (digalactosyl monoglyceride).
Optionally, the lipolytic enzyme may also have triacylglycerol lipase activity (EC i.e. hydrolytic activity for carboxylic ester bonds in triglycerides, e.g. 1,3-specific activity, particularly on long-chain triglycerides such as olive oil. The enzyme may have a substrate specificity for hydrolyzing long-chain fatty acyl groups rather than short-chain groups, e.g. expressed as a high ratio of activities on olive oil and tributyrin, e.g. a ratio SLU/LU>3 as described in WO 0032758.
LPL/PL ratio (PLARN) Phospholipase activity is determined at 30 *C using 4% lecithin (phosphatidyl choline) in 50 mM sodium acetate, 5 mM CaCI2, pH 5.0. One unit of phosphollpase activity is defined as 1 mmol free fatty acids released per minute per mg enzyme using the above conditions.
00 Lysophospholipase activity is determined at 30 °C using 1% lysolechitin in mM sodium acetate, 5 mM CaCI2, pH 5.0. One unit of lysophospholipase activity is defined N as 1 mmol free fatty acids released per minute per mg enzyme using the above conditions.
The lysolechitin may be an equilibrium mixture or pure 1- lysolechitin in the case of a phospholipase Al and pure 2- lysolechitin in the case of a phospholipase A2.
SThe PLARN ratio is defined as the lysophospholipase activity divided by the phospholipase activity, both determined by the above methods.
Relative activity on lysopholipids and phospholipids (RLPLA) This activity measurement expresses the relative activity on lysophosphatidyl choline and phosphatidyl choline in an equimolar mixture.
00 More specifically the assay is carried out as follows: The activity at different concen- O trations of phospholipase is determined at 30'C blending 1:1 solutions of phosphatidyl choline and lysophosphatidyl choline (25mM) in 50mM NaOAc buffer (pH 50pl enzyme solution having 0.1 or 2.5 mg enzyme protein per ml) is added to the substrate solution and allowed to react for 30 minutes. 100pl of the sample is inactivated at 95'C for 5 minutes and dissolved in 900pl CHCI3/MeOH 50%/50%. The sample is centrifuged at 14000rpm for 2 minutes. The supernatant is analyzed by HPLC after filtering through a 0.45pm filter. Column: Microsorb-MV 100Si 250mm column (analytical instruments). Mobile phases: A: 80% CHCi3, 19.5% MeOH, 0.5% NH40H; B: 60% CHCI3, 34% MeOH, 0.5% NH40H, 5.5% H20. Gradient: 0-3 minutes 100% A, 3-23 minutes 100% B, 23-45 minutes 100% A. Injection volume Detector: Sedere, Sedex 75 light scattering, Temp 40°C, pressure 3.5 Bar. The RLPLA is then measured as the depletion of phosphatidyl choline relative to lysophosphatidyl choline.
A variant with a lower RLPLA value indicates a higher accumulation of lysophospholipid under the conditions of analysis.
The relative activity can be expressed as "RLPLA ratio" by measuring lysolecithin hydrolysis at an enzyme dosage of 0.1 mg/ml and lecithin hydrolysis at a dosage of mg/ml, and taking the ratio of the two.
Plate assay Plates including each of the substrates may be prepared in analogy with WO 0032758 using suitable pH and substrate concentration. Optionally, other ingredients such as flour may be included. A suitably diluted enzyme solution is applied to holes in the plates, and clearing zones are read after incubation for a suitable time at a suitable temperature.
Preparation of lipolytic enzyme The lipolytic enzyme may be obtained by preparing variants of a parent lipolytic enzyme by altering its amino acid sequence and screening for a variant with an improved activ- 00 ity ratio. The parent lipolytic enzyme may have phospholipase activity, DGDG hydrolytic activ- 8 ity and/or triacylglycerol lipase activity. Variants may be prepared from the parent lipolytic enzyme by known methods, e.g. by subjecting a DNA sequence encoding the parent lipolytic enzyme to site-directed mutagenesis, localized random mutagenesis or site-saturation mutagenesis, e.g. using methods described In WO 0032758. Resulting DNA sequences may be further modified by gene shuffling and directed evolution.
Parent lipolytic enzyme The lipolytic enzyme to be used in the present Invention is one that can hydrolyze Sester bonds. Such enzymes include, for example, lipases, such as triacylglycerol lipase (EC 00 10 lipoprotein lipase (EC 3.1.1.34), monoglyceride lipase (EC 3.1.1.23), phosphollpase SAl or A2 (EC 3.1.1.26, lysophospholipase (EC galactolipase (EC 3.1.1.26), ferulic acid esterase and esterase (EC 3.1.1.1, EC 3.1.1.2).
The parent lipolytic enzyme may be the Thermomyces lanuginosus lipase (Humicola lanuginosa lipase) (EP 305216) or it may have an amino acid sequence with at least 50 identity at least 90 identity). The amino acid sequence of the T. lanuginosus lipase is shown in US 5869438 and as seq14 in Fig. 2 of this application.
Thus, the parent lipolytic enzyme may be a naturally occurring enzyme as described at pages 5-6 of WO 0032758. Examples are the lipolytic enzymes from the following organisms. They are known in the prior art; and their amino acid sequences are given in the attached sequence listing.
1. Absidia reflexa 2. Absidia corymbefera 3. Rhizmucor miehei 4. Rhizopus delemar (oryzae) 5. Aspergillus niger 6. Aspergillus tubingensis 7. Fusarium oxysporum 8. Fusarium heterosporum 9. Aspergillus oryzae 10. Penicilium camembertii 11. Aspergillus foetidus 12. Aspergillus niger 13. Aspergillus oryzae 14. Thermomyces lanuginosus (Humicola lanuginosa) As indicated above, the amino acid to be altered may be determined on the basis of an alignment of the parent lipolytic enzyme with the T. lanuginosus lipase. Fig. 2 shows an 00 alignment of the amino acid sequences of the above fungal lipolytic enzymes, based on a Scomparison of the available 3-dimensional structures: SOther amino acid sequences may be aligned with those shown In Fig. 2 by using the SGAP alignment to the most homologous sequence found by the GAP program. GAP is provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin,
USA
53711) (Needleman, S.B. and Wunsch, (1970), Journal of Molecular Biology, 48, 443- The following settings are used for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
8 10 Alternatively, the parent lipolytic used in the present invention may be a variant of the oO above, e.g. a variant of the T. lanuginosus lipase (SEQ ID NO: 14) or the F. oxysporum li- Spase/phospholipase (SEQ ID NO: A variant with phospholipase activity or galactolipase Sactivity may be used, e.g. as described in Example 5, 6 or 13 of WO 0032758. Particular examples are variants of SEQ ID NO: 14 with the following amino acid alterations: L259S G266D G91A +D96W +E99K +G263Q +L264A +1265T +G266D +T267A +L269N +270A+ 271G+ 272G+ 273F +274S G266E G263A +G266A E1SPCRPRP +E239C +Q249R +G266A E1SPCRPRP +E239C +Q249R +G266S D96S G266A D96S G266S D96S G266W E1SPPCGRRP +D96S +E239C +Q249R +G263D +L2641 +1265N +G266E +T267GS Three-dimensional model Fig. 1 gives the coordinates of a three-dimensional model of the T. lanuginosus lipase docked with a phospholipid as substrate: 1-palmetoyl-2-oleylglycero-sn-3phosphocholine (POPC). This may be used as a starting point for building a similar model for any given fungal lipolytic enzyme. Using this model, the following amino acid residues are found to be within 10 A, 7 A and 5 A of an atom of the substrate (LIP1 in the pdb structure shown in Fig. 1): 00 10 A: 17-18, 20-23, 26, 37, 39, 62, 64, 80-96, 110-113, 144-151, 171-177, 200-21.1, S213, 215, 227, 253-261, 263-269.
N 7 A: 21, 81-95, 110, 113, 145-148, 150, 172-175, 201-208, 213, 254-256, 258-259, S264-269.
5 A: 21, 82-86, 89-90, 92-93, 95, 110, 113, 145-147, 174, 202-203, 206-208, 255, S258-259, 265-268.
More particularly, amino acid alterations may be made at one or more positions corresponding to the following amino acids in the T. lanuginosus lipase (SEQ ID NO: 14): Y212, S R84, S85, E87, D96, V203, L206, L227, P253, D254, P256, P257 and/or Y261, particularly one or more alterations corresponding to Y21V/K, R84W/A/G/Y/S, S85D, E87A, D96F/KIG, 00 V2031, L206F, P253Q, D254*, P256N, P257S and/or Y261Q.
SFurther, amino acid alterations may be made at one or more positions corresponding to H257, S142, S80, D263 and/or Y21 of the F. oxysporum lipase/phospholipase (SEQ ID NO: particularly one or more corresponding to H257W, S142A, S80T, D263G and/or Y21W.
Also, amino acid alterations may be made at the C-terminal or at any position downstream of L269 of SEQ ID NO: 14. Such alteration may be addition or deletion of a peptide extension or deletion of a peptide extension of one or more amino acids 1-50 amino acids such as 2-15) at the C-terminal.
Amino acid alteration The amino acid alteration may be substitution with a larger amino acid. The amino acid residues are ranked by size as follows from smallest to largest: G, A, S, C, V, T, P, L, I, N, D, M, E, Q, K, H, R, F, Y, W An amino acid residue within 10 A (or 7 A or 5 A) of a C atom in the alkyl group R of R-COO attached to snl of the lyso-phospholipid may be substituted with an amino acid residue which is larger or more hydrophilic.
An amino acid residue within 10 A (or 7 A or 5 A) of an atom (other than H) of the phosphate group attached to sn3 the O atom at sn3 or any atom beyond that) may be substituted with an amino acid which is larger or more hydrophobic.
Amino acid residues are ranked as follows from most hydrophilic to most hydrophobic: R, K, E, D, N, Q, H, S, T, Y, C, M, G, A, V, P, L, I, F, W Lipolytic enzyme variant Starting from a variant having phospholipase activity derived from the T. lanuginosus lipase, and improvement regarding increased ratio of lecithin/lysolecithin(snl) activity and 00 lowered activity against lysolecithin (snl) of lysolecithin in general, or/and with improved sni Slecithase activity may be achieved by use of the following concepts.
One concept is to lower the binding energy of sni acyl chain and in this way increase the ratio of activity lecithln/lysolecithin(snl). Secondary to increase sn2 binding to favour lecithin rather than lysolecithin.
SThus, 206, 95, 203 and 93 may be made smaller and more hydrophillc. Also, positions 253, 255 and 256 may be made bigger. Some particular examples of such variants are: I L206V/S/T/A lrn V203T/S/A 0 10 F951/L/Y 00 L93V/I/A/T SA doped library 206/203 and 95/93. appr. 90% wt and appr 10% variant may be used.
A second concept is to make libraries in the contacts to both acyl chains found docked structures, and in the regions close to the substrate found by comparison of good and bad lysolecithase active homologous enzymes. The regions will be doped according to the homologous enzymes sequence.
Thus, region 265-269 is of interest, e.g. P253. Some particular examples of such variants are: A doped library 247-260 may be used, optionally together with doped 1202P and L206V. The doping may be appr. 90%wt and appr. 10% variants.
P253TG/L D254S/L 1255 P2561/A A257D/A L259 W260H Proline removal(s): P256X P253X together with 1202P L227D Library 247-260 and 206, 95, 203 and 93 may be combined.
00 Amino acid Identity The lipolytic enzyme of the invention and the parent lipolytic enzyme may have an Samino acid identity of at least 50 (particularly at least 90 e.g. more than 95 or more than 98 with the T lanuginosus lipase (SEQ ID NO: 14).
The degree of identity may be suitably determined by means of computer programs Sknown in the art, such as GAP provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science SDrive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, (1970), Journal Sof Molecular Biology, 48, 443-45), using GAP with the following settings for polypeptide se- 8 10 quence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1.
00 SUse of lipolytic enzyme variant Hydrolysis of phospholiid A variant with phospholipase activity can be used to prepare lysophospholipid (e.g.
lyso-lecithin) by treating the corresponding phospholipld with the variant, e.g. as described in EP 870840, JP-A 10-42884, JP-A 4-135456 or JP-A 2-49593. The variant can also be used to make mayonnaise, e.g. as described in EP 628256, EP 398666 or EP 319064.
Advantageously, a low ratio of lysophospholipase/phospholipase activity can lead to a high degree of phospholipid hydrolysis with a low degree of lysophospholipid hydrolysis.
This may allow the use of long reaction time and the use of phospholipid with a high lysophospholipid content, e.g. from cereals such as oats.
Baking Lipolytic enzymes according to the invention have improved baking performance, e.g. a lower dough stickiness, a better dough extensibility and elasticity, a better dough stability, a better crumb structure of the baked product, a larger loaf volume and/or improved resistance to over-proofing or other abuse.
The invention provides a baking additive in the form of a granulate, an agglomerated powder or a stabilized liquid, comprising a lipolytic enzyme which: a) has phospholipase activity, and b) has a lysophospholipase to phospholipase ratio corresponding to PLARN below 500 or RLPLA .below The baking additive may have a narrow particle size distribution with more than 95 (by weight) of the particles in the range from 25 to 500 pm.
Granulates and agglomerated powders may be prepared by conventional methods, e.g. by spraying the lipolytic enzyme onto a carrier in a fluid-bed granulator. The carrier may consist of particulate cores having a suitable particle size. The carrier may be soluble or in- 00 0O 0O oo fc i^ soluble, e.g. a salt (such as NaCI or sodium sulfate), a sugar (such as sucrose or lactose), a sugar alcohol (such as sorbitol), starch, rice, corn grits, or soy. Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods.
5 The invention further relates to a pre-mix comprising flour and the lipolytic enzyme described above. The pre-mix may contain other dough-improving and/or bread-improving additives, e.g. any of the additives, including enzymes, mentioned above.
The invention also provides a method of preparing a dough or a baked product prepared from dough. The method may comprise preparing a variant by the above method and adding it to the dough. Alternatively, the method may comprise: a) testing at least one lipolytic enzyme for its hydrolytic activities towards intact phospholipid (PL) and lyso-phospholipid
(LPL),
b) selecting a lipolytic enzyme having a hydrolytic activity ratio for LPL/PL corresponding to PLARN below 500, and c) adding the selected lipolytic enzyme to the dough.
Dough The dough generally comprises wheat meal or wheat flour and/or other types of meal, flour or starch such as corn flour, corn starch, rye meal, rye flour, oat flour, oat meal, soy flour, sorghum meal, sorghum flour, rice starch, rice flour, potato meal, potato flour or potato starch. The dough may be fresh, frozen or par-baked. It may particularly be a leavened dough.
The dough may also comprise other conventional dough ingredients, proteins, such as milk powder, gluten, and soy; eggs (either whole eggs, egg yolks or egg whites); an oxidant such as ascorbic acid, potassium bromate, potassium iodate, azodicarbonamide (ADA) or ammonium persulfate; an amino acid such as L-cysteine; a sugar; a salt such as sodium chloride, calcium acetate, sodium sulfate or calcium sulfate.
The dough may comprise fat (triglyceride) such as granulated fat or shortening, but the invention is particularly applicable to a dough where less than 1 by weight of fat (triglyceride) is added, and particularly to a dough which is made without addition of fat.
The dough may further comprise an emulsifier such as mono- or diglycerides, diacetyl tartaric acid esters of mono- or diglycerides, sugar esters of fatty acids, polyglycerol esters of fatty acids, lactic acid esters of monoglycerides, acetic acid esters of monoglycerides, polyoxyethylene stearates, or lysolecithin, but the invention is particularly applicable to a dough which is made without addition of emulsifiers (other than optionally phospholipid).
00 Baked product 0 The process of the invention may be used for any kind of baked product prepared from dough, either of a soft or a crisp character, either of a white, light or dark type. Examples are bread (In particular white, whole-meal or rye bread), typically in the form of loaves or rolls, S 5 -French baguette-type bread, pita bread, tortillas, cakes, pancakes, biscuits, cookies, muffins, pie crusts, crisp bread, steamed bread, pizza and the like.
Additional enzyme Optionally, an additional enzyme may be used together with the lipolytic enzyme.
The additional enzyme may be a second lipolytic enzyme as described in PCT/ DK01/00472), an amylase, particularly an anti-staling amylase, an amyloglucosidase, a 00 cyclodextrin glucanotransferase, or the additional enzyme may be a peptidase, in particular San exopeptidase, a transglutaminase, a cellulase, a hemicellulase, In particular a pentosanase such as xylanase, a protease, a protein disulfide isomerase, a protein disulfide isomerase as disclosed in WO 95/00636, a glycosyltransferase, a branching enzyme (1,4-aglucan branching enzyme), a 4-a-glucanotransferase (dextrin glycosyltransferase), a lactase (galactosidase), or an oxidoreductase, a peroxidase, a laccase, a glucose oxidase, a pyranose oxidase, a lipoxygenase, an L-amino acid oxidase or a carbohydrate oxidase.
The amylase may be a fungal or bacterial alpha-amylase, e.g. from Bacillus, particularly B. licheniformis or B. amyloliquefaciens, or from Aspergillus, particularly A. oryzae, a betaamylase, e.g. from plant soy bean) or from microbial sources Bacillus). The amylase may be an anti-staling amylase, as described in WO 99/53769, i.e. an amylase that is effective in retarding the staling (crumb firming) of baked products, particularly a maltogenic alpha-amylase, e.g. from Bacillus stearothermophilus strain NCIB 11837.
Other uses The lipolytic enzyme variant may also be used in the production of pasta and noodles in analogy with EP 1057415.
A lipolytic enzyme variant with phospholipase activity may be used in cheese production as described in WO 00/54601.
EXAMPLES
Example 1: Variants based on a T. lanuginosus llpase variant A prior-art variant of the T. lanuginosus lipase with phospholipase activity was chosen as the starting point (parent lipolytic enzyme), and variants were prepared by introducing further amino acid alterations into the prior-art variant.
Experiment A Activities of the new variants were determined with lecithin and lysolecithin (pure 1phosphatidyl choline, 1-lysolecithin) as substrates by the methods described above. More .C specifically, 1.7 mL of the reaction mixture was shaken for between 15 and 90 min in an Eppendorf tube shaken at 1300 rpm by an "Eppendorf Thermomixer comfort". The enzyme was inactivated at 95 C for 5 min, and centrifuged at 14000 rpm by Eppendorf centrifuge 5417R. The liberated fatty acids were determined (relative to a control sample where the N enzyme was inactivated before it was added to the substrate) by NEFA C test from Wako foll lowing the ACS-ACOD method described for the NEFA-C test.
Three variants were found to have phospholipase activity and a to have a lower ratio C of lysophospholipase to phospholipase than the prior-art variant.
S00R84W +G91A F +K Q A T 2 A SR84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N G91A +D96W +E99K +L227G +G263Q +L264A +1265T +G266D +T267A +L269N R84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266S +T267A +L269N +270A +271G +272G +273F +274S Experiment B Activities of further variants were determined with lecithin and lysolecithin (mixture of 1- and 2-lysolecithin) as substrates at 0.1 and 2.5 mg/ml by the RLPLA method described above. All variants were found to have a high activity on lysolecithin compared to lecithin.
Variants having the following amino acid alterations compared to SEQ ID NO: 14 were found to have phospholipase activity and a to have a lower ratio of lysophospholipase to phospholipase than the prior-art variant.
SPPCGRRP(-E) +Y21K +E99N +N101S +E239C +Q249R G91A +D96K +E99K +G263Q +L264A +1265T +G266D +T267A +L269N Y21V +R84G +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S +D62W +R84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N +D62S +G91A +D96W +E99K +W221R +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S R84A S85D E87A +G91A +D96G +K98E +E99D G91A +D96W +E99K +P250N +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S 00 G91A +D96W +E99K +P256N +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S R84W +G91A +096W +E99K *Y261Q +G263Q '-L264A +1265T +G266D +T267A +L269N +270A +271 G +272G +273F +274S G91A +096W +E99K +P250L +P253Q +D254DEL +P257S +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271 G +272G +273 F +274 S IND R84Y G91A D96F E99K G263Q L264A 1265T G266D T267A L269N R84S G91A D96F E99K E129A +V203i +L206F G263Q L264A 1265T G266D T267A L269N 00 Example 2: Variants of F. oxysporum lpaselphospholipase Variants of the F. oxysporum lipase/phospholipase were prepared, having the follow- Ing amino acid alterations compared to SEQ ID NO: 7: H257W S142A V1 570 +S271 P +A1 27T D263G Y21W The following variants with modified C-terminal sequences were prepared by making the substitutions R274A and/or R284A to remove one or two cleavage points for the Kex-2 protease: R274A +275YRSAESVDKR R274A +275YRSAESVDKAATMTDAELEKKLNSYVQMDKEYVKNNQARS Activities of the variants and the parent enzyme were determined as in Example 2.
Compared to the parent enzyme, the variants were found to have lower activity on lysolecithin and a lower ratio of lysolecithin activity to lecithin activity.
Example 3: Preparation of dough Doughs were prepared from Meneba flour according to the European straight dough method (ABF-SP 1201 with 40 ppm Fungamyl Super MA (Novozymes), 40 ppm ascorbic acid, and different dosages of lipolytic enzyme.
The stickiness of the dough was evaluated an a 1-10 scale by the baker as the deoO O gree to which a dough adheres to ones hands or other surfaces, where 5 is identical to a con- Cl trol without addition of lipolytic enzyme, 1 is the lowest degree of stickiness and 10 is the highest degree of stickiness.
C 5 The extensibility of the dough was evaluated an a 1-10 scale by the baker as the degree to which a dough can be stretched without tearing where 5 is identical to a control without addition of lipolytic enzyme, 1 indicates the lowest (shortest) extensibility and 10 indicates the highest (longest) extensibility The elasticity of the dough was evaluated an a 1-10 scale by the baker as the degree to which a dough tends to recover its original shape after release from a deforming force, where 5 is identical to a control without addition of lipolytic enzyme, 1 indicates the 00 0lowest (weakest) elasticity and 10 indicates the highest (strongest) elasticity.
C A lipolytic enzymes prepared in Example 1 was tested, and the prior-art variant was tested for comparison. The results were as follows Experiment A
PLARN
Lipolytic en- Dosage Stickiness Extensibility Elasticity zyme ratio Invention 0.2 mg/kg dough 690 5 6 4 Prior art 250 LU/kg dough 5800 5 7 3 Experiment
B
Lipolytic en- RLPLA Lpolytic en- Dosage Stickiness Extensibility Elasticity zyme ratio Invention 0.2 mg/kg flour 1.06 4 4 6 Prior art 250 LU/kg dough 1.58 5 5 The results show that lipolytic enzymes with a lower ratio of lysolecithin activity to lecithin activity make doughs with a desirable combination of lower extensibility and higher elasticity than the prior-art lipolytic enzymes, and they furthermore tend to make a less sticky dough.
Claims (2)
- 2. A method of producing a lipolytic enzyme variant comprising: a) selecting a parent fungal lipolytic enzyme, b) in the parent lipolytic enzyme selecting at least one amino acid residue corresponding to any of residues 17-18, 20-23, 26, 37, 39, 62, 64, 80-96, 110-113,
- 144-151, 171-177, 200-211, 213, 215, 227, 253-261 and 263-269 of the T. lanuginosus lipase (SEQ ID NO: 14), c) altering the selected amino acid, d) optionally, altering one or more amino acids other than those selected, e) preparing the variant resulting from the preceding steps, f) testing hydrolytic activities of the variant towards the bond B-C of a first substrate having the general formula A-B-C and towards the bond B'-C of a second substrate having the general formula C where: i) A and A' are fatty acyl groups, ii) B and B' are oxygen or sulfur 00 iii) C is a polyol with B, B' and B" attached to OH groups, optionally hav- ing other functional groups, and optionally having a hydrophilic group at- 1 tached to an OH group, g) selecting a variant having a ratio of activity on the first substrate to activity on the C 5 second substrate which is lower than the parent lipolytic enzyme, and Sh) producing the selected variant. I 3. The method of either preceding claim wherein the first substrate is a lyso-phospholipid Sand the second substrate is a phospholipid. 4. The method of the preceding claim wherein the parent lipolytic enzyme has phospholi- pase activity, particularly phospholipase Al activity. The method of the preceding claim wherein the parent lipolytic enzyme also has digalac- tosyl diglyceride hydrolyzing activity and optionally triacylglycerol lipase activity. 6. The method of any preceding claim wherein the parent lipolytic enzyme has an amino acid sequence which is at least 50 (particularly at least 90 identical to that of the Ther- momyces lanuginosus lipase (SEQ ID NO: 14). 7. The method of the preceding claim wherein the alterations comprise substitution of at least one of L93, F95, V203 and L206 with an amino acid residue which Is smaller and/or more hydrophilic. 8. The method of the preceding claim wherein the alterations comprise at least one of the substitutions L206V/S/T/A, V203T/S/A, F9511L/Y and L93V/I/AT. 9. The method of claim 5 wherein the alterations comprise substitution of at least one of P253,1255 and P256 with an amino acid which is larger. The method of claim 5 wherein the alterations comprise an amino acid alteration in the region 247-260 or 265-269. 11. The method of the preceding claim wherein the alterations comprise substitution of at least one of P253 and P256 with a different amino acid residue. 12. The method of claim 5 wherein the alterations comprise a substitution L227D, P253T/G/L, D254S/L, 1255, P256L/A, A257D/A, L259 or W260H. 00 13. The method of claim 5 wherein the alterations comprise an amino acid alteration in the region 247-260 and an alteration of amino acid L93, F95, V203 and L206. 14. The method of any of claims 5-12 wherein the parent lipolytic enzyme compared to the T Ianugfnosus lipase (SEQ ID NO: 14) comprises an amino acid alteration at a position corre- sponding to R81, R84, S85, G263, L264, 1265, G266, T267 or L269 and/or a peptide exten- sion of 1-10 amino acids art the C-terminal. r- 15. A method of preparing a dough or a baked product made from dough, comprising prepar- ing a lipolytic enzyme variant by the method of any preceding claim and adding the lipolytic enzyme variant to the dough. 00 16. A variant of a parent fungal lipolytic enzyme which variant comprises an amino acid al- teration corresponding to R84GIAIYIS or L206F of SEQ ID NO: 14, has phospholipase activ- ity and has a lysophospholipase to phospholipase ratio corresponding to PLARN below 500 or RLPLA below 17. A lipolytic enzyme having an amino acid sequence derived from the T. lanuginosus lipase (SEQ ID NO: 14) comprising the following amino acid alterations: a) R84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N, b) G91A +D96W +E99K +L227G +G263Q +L264A +1265T +G266D +T267A +L269N, c) R84W +G9IA:D96F +E99K +G263Q +L264A +1265T +G266S +T267A +L269N +270A +271 G +272G +273F +274S, d) SPPCGRRP(-E) +Y21K +E99N +N1OIS +E239C +Q249R, e) G9IA +D96K +E99K +G263Q +L264A +1265T +G266D +T267A +L269N, f) Y21V +RB4G +G91A:D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, g) V60G +D62W +R84W +G91A +D96F +E99K +G263Q +L264A +1265T +G266D +T267A +L269N, h) V6OA +D62S +G9IA +D96W +E99K +W221R +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, i) R84A S85D E87A +G91IA +D96G +K98E +E99D, J) G91A +D96W +E99K +P250N +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, k) G91A +D96W +E99K +P256N +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S. 00 1) R84W +G91A +096W +E99K +Y261Q +G263Q +L264A +1265T +G266D +T267A -'L269N +270A +271 G +272G +273F +274S, m) G91A +096W +E99K +P250L +P253Q +0254DEL +P257S +G263Q +L264A +1265T +G266D +T267A +L269N +270A +271G +272G +273F +274S, r- 5 n) R84Y +G91A +D96F +E99K G263Q +L264A +1265T +G266D +T267A L269N, or o) R84S G91A D96F E99K E129A +V2O3i +L206F G263Q L264A 1265T G266D T267A 1-269N. C) 18. A lipolytic enzyme having an amino acid sequence derived from a Fusarium lipase com- 00 10 prising at least one amino acid alteration corresponding to the following in the Fusarium ox- ysporum lipase(phosphollpase (SEQ ID NO: 7): C1a) H257W, b) S142A, c) VI157D, d) S271 P, e) S8OT, f) A127T, g) D263G, h) Y21W, i) S8OT, j) R274A, k) 275YRSAESVDKR or 1) 275YRSAESVDKAATMTDAELEKKLNSYVQMDKEYVKNNQARS 19. A lipolytic enzyme which: a) has an amino acid sequence having at least 90 identity to that of the Thermo- myces Ianuginosus lipase (SEQ ID NO: 14) or the Fusarium oxysporum li- pase/phospholipase (SEQ ID NO: 7), b) has phospholipase activity, and c) has a lysophospholipase to phospholipase ratio corresponding to PLARN below 500 or RLPLA below Dated 7 February, 2008 Novazymes A/S Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008200576A AU2008200576A1 (en) | 2002-01-16 | 2008-02-07 | Lipolytic enzyme variants and method for their production |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200074 | 2002-01-16 | ||
| AU2003203139A AU2003203139B2 (en) | 2002-01-16 | 2003-01-16 | Lipolytic enzyme variants and method for their production |
| AU2008200576A AU2008200576A1 (en) | 2002-01-16 | 2008-02-07 | Lipolytic enzyme variants and method for their production |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003203139A Division AU2003203139B2 (en) | 2002-01-16 | 2003-01-16 | Lipolytic enzyme variants and method for their production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2008200576A1 true AU2008200576A1 (en) | 2008-02-28 |
Family
ID=39243845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008200576A Abandoned AU2008200576A1 (en) | 2002-01-16 | 2008-02-07 | Lipolytic enzyme variants and method for their production |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2008200576A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111303298A (en) * | 2020-02-19 | 2020-06-19 | 李瑛� | Fusion protein containing phosphatase, and product and application thereof |
| CN113840919A (en) * | 2019-03-15 | 2021-12-24 | 丹尼斯科美国公司 | Improved lipase for defoaming |
-
2008
- 2008-02-07 AU AU2008200576A patent/AU2008200576A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113840919A (en) * | 2019-03-15 | 2021-12-24 | 丹尼斯科美国公司 | Improved lipase for defoaming |
| CN111303298A (en) * | 2020-02-19 | 2020-06-19 | 李瑛� | Fusion protein containing phosphatase, and product and application thereof |
| CN111303298B (en) * | 2020-02-19 | 2023-03-21 | 李瑛� | Fusion protein containing phosphatase, and product and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003203139B2 (en) | Lipolytic enzyme variants and method for their production | |
| US8298800B2 (en) | Lipolytic enzyme variants | |
| US9247753B2 (en) | Preparation of dough or baked products | |
| US8916368B2 (en) | Lipases and uses thereof | |
| AU2008200576A1 (en) | Lipolytic enzyme variants and method for their production | |
| WO2018114912A1 (en) | Lipolytic enzyme variants | |
| CA2412533C (en) | Method of preparing a dough or a baked product made from a dough, with addition of lipolytic enzymes | |
| CA3046153A1 (en) | Lipolytic enzyme variants | |
| AU2001272359A1 (en) | Method of preparing a dough or a baked product made from a dough, with addition of lipolytic enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |